Design of the trial of org 10172 in acute stroke treatment (TOAST)

Controlled Clinical Trials

Volumn 18, Issue 4, 1997, Pages 358-377

  Adams Jr , Harold P ^a   Woolson, Robert F ^a   Clarke, William R ^a   Davis, Patricia H ^a   Bendixen, Birgitte H ^a   Love, Betsy B ^b   Wasek, Patricia A ^a   Grimsman, Karla J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b University of Iowa ^*

Author keywords

Acute treatment; Antithrombotic therapy; Clinical trials; Design; Ischemic stroke

Indexed keywords

CHONDROITIN SULFATE; DANAPAROID; DERMATAN SULFATE; FIBRINOLYTIC AGENT; HEPARAN SULFATE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; CEREBROVASCULAR DISORDERS; CHONDROITIN SULFATES; DERMATAN SULFATE; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HEPARITIN SULFATE; HUMANS; MALE; MIDDLE AGED; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0031203444     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0197-2456(97)00012-3     Document Type: Article

References (43)

1. Adams HP Jr, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke. A statement for health care professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994;25:1901-1914.
2. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
3. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-1593.
4. Britton M, Roden A. Progression of stroke after arrival at hospital. Stroke 1985;16:629-632.
5. Duke RJ, Turpie AG, Bloch RF, et al. Clinical trial of low-dose subcutaneous heparin for prevention of stroke progression. Natural history of acute partial stroke and stroke-in-evolution. In: Reivich M and Hurtig HI, eds. Cerebrovascular Disease. New York: Raven Press; 1983;399-405.
6. Marsh EE III, Adams HP Jr, Biller J, et al. Use of antithrombotic drugs in the treatment of acute ischemic stroke. A survey of neurologists in practice in the United States. Neurology 1989;39:1631-1634.
7. Anderson DC. How Twin Cities neurologists treat ischemic stroke. Policies and trends. Arch Neurol 1993;50:1098-1103.
8. Kappelle LJ, Adams HP Jr, Torner JC, et al. Physician attitudes towards acute stroke. A comparison of primary care physicians in Iowa and The Netherlands. Cerebrovasc Dis 1993;3:364-369.
9. Sandercock PAG, van den Blet AGM, Lindley RI, et al. Antithrombotic therapy in acute ischaemic stroke. An overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993;18:25-28.
10. Gordon DL, Linhardt R, Adams HP Jr. Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clin Neuropharm 1990;13:522-543.
11. Hirsh J, Rashcke R, Warkentin TE, et al. Heparin. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S-275S.
12. Cade JF, Wood M, Magnani HN, et al. Early clinical experience of a new heparinoid, Org 10172, in prevention of deep vein thrombosis. Thromb Res 1987;45:497-503.
13. Ten Cate H, Henny CP, Buller HR, et al. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease. Ann Neurol 1984;15:268-270.
14. Turpie AGG, Levine MN, Hirsh J, et al. Double-blind randomized trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;1:523-526.
15. Magnani HN. Heparin-induced thrombocytopenia (HIT). An overview of 230 patients treated with Orgaran (Org 10172) Thromb Haemost 1993;70:554-561.
16. Biller J, Massey EW, Marier JR, et al. A dose escalation study of Org 10172 (low molecular weight heparinoid) in the treatment of acute cerebral infarction. Neurology 1989;39:262-265.
17. Massey EW, Biller J, Davis JN, et al. A study of large dose infusions of heparinoid Org 10172 in ischemic stroke. Stroke 1990;21:1289-1292.
18. Mahoney FI, Barthel DW. Function evaluation. The Barthel index. Maryland State Med J 1965;14:61-65.
19. Jennet B, Bond M. Assessment of outcome after severe brain damage. A practical scale. Lancet 1975;1:480-484.
20. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction. A clinical examination scale. Stroke 1989;20:864-870.
21. Wade DT. Measurement in Neurological Rehabilitation. Oxford: Oxford University Press; 1992;177-178, 237-238.
22. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke 1993;23:35-41.
23. Haley EC Jr, Kassell NF, Torner JC, et al. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. J Neurosurg 1993;78:537-547.
24. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol 1989;46:660-662.
25. Albanese M, Clarke WR, Adams HP Jr, et al. Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke. The program developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke 1994;25:1746-1751.
26. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J National Cancer Inst 1959;22:719-748.
27. Breslow NE, Day NE. Statistical Methods in Cancer Research, Volume 1. The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer; 1980:142.
28. Fleiss JL. Design and Analysis of Clinical Studies, New York: John Wiley & Sons; 1987:186-219.
29. Lan KKG, DeMets DL. Group sequential procedures. Calendar versus information time. Stat Med 1989;8:1191-1198.
30. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663.
31. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrika 1979;35:549-556.
32. Adams HR Jr, Woolson RF. Clinical trials in acute ischemic stroke. Problems in design and interpretation. J Stroke Cerebrovasc Dis 1991;1:134-141.
33. Adams HP Jr. Trials of trials in acute ischemic stroke. The Humana lecture. Stroke 1993;24:1410-1415.
34. Biller J, Love B, Marsh E, et al. Spontaneous improvement after acute ischemic stroke. A pilot study. Stroke 1990;21:1008-1012.
35. Rothrock JR, Clarke WM, Lyden PD. Spontaneous early improvement following ischemic stroke. Stroke 1995;26:1358-1360.
36. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.
37. Black P McL, Crowell RM, Abbott WM. External pneumatic calf compression reduces deep vein thrombosis in persons with ruptured intracranial aneurysms. Neurosurgery 1986;18;25-28.
38. Duke RJ, Bloch RF, Turpie AGG, et al. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. A randomized controlled trial. Ann Intern Med 1986;105:825-828.
39. Madden KP, Karanjia PN, Adams HP Jr, et al. Accuracy of initial stroke subtype in the TOAST study. Neurology 1995;45:1975-1979.
40. Gordon DL, Bendixen BH, Adams HP Jr, et al. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke. Implications for clinical trials. Neurology 1993;43:1021-1027.
41. McDowell FM, Brott TG, Goldstein M, et al. National Stroke Association Consensus Statement. Storek. The first six hours. J Stroke Cerebrovasc Dis 1993;3:133-144.
42. Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for stroke. Part I. Pilot studies of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-640.
43. Haley EC Jr, Levy DE, Brott RG, et al. Urgent therapy for stroke. Part II. Pilot studies of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-645.